Inhaltsbereich
| 227 Einträge | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 › » |
Seite 1 / 12
 Druckansicht
|
| Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. |
| Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B |
| The Journal of pathology. 2015 May 26. doi: 10.1002/path.4567 |
| PMID: 26011651 |
| Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. |
| Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, van Schoonhoven S, Cichna-Markl M, Koellensperger G, Keppler BK, Berger W, Heffeter P |
| Cancer letters. 2015 Mar 5. pii: S0304-3835(15)00164-0. doi: 10.1016/j.canlet.2015.02.049 |
| PMID: 25749419 |
| Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. |
| Spiegl-Kreinecker S, Lötsch D, Ghanim B, Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J, Berger W |
| Neuro-oncology. 2015 Feb 13. pii: nov010. doi: 10.1093/neuonc/nov010 |
| PMID: 25681309 |
| Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts. |
| Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R |
| Molecular cancer therapeutics. 2015 Jan 22. pii: 1535-7163.MCT-14-0701. doi: 10.1158/1535-7163.MCT-14-0701 |
| PMID: 25612618 |
| Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. |
| Gauglhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, Pirker C, Mohr T, Heinzle C, Holzmann K, Marian B, Schulte-Hermann R, Berger W, Krupitza G, Grusch M, Grasl-Kraupp B |
| Carcinogenesis. 2014 Jul 16. pii: bgu151. doi: 10.1093/carcin/bgu151 |
| PMID: 25031272 |
| Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones. |
| Heffeter P, Pirker C, Kowol CR, Herrman G, Dornetshuber R, Miklos W, Jungwirth U, Koellensperger G, Keppler BK, Berger W |
| Biochemical pharmacology. 2012 Mar 15. pii: S0006-2952(12)00196-7. doi: 10.1016/j.bcp.2012.03.004. pmc: PMC3342514 |
| PMID: 22426010 |
| Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. |
| Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K |
| Neuroendocrinology. 2012 Apr 27. pii: 000337257. doi: 10.1159/000337257 |
| PMID: 22378048 |
| Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. |
| Metzner T, Bedeir A, Held G, Peter-Vörösmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, Pirker C, Micksche M, Berger W, Heffeter P, Grusch M |
| The Journal of investigative dermatology. 2011 Jul 14. pii: jid2011177. doi: 10.1038/jid.2011.177. pmc: PMC3383623. mid: UKMS48843 |
| PMID: 21753785 |
| DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. |
| Schmidt WM, Uddin MH, Dysek S, Moser-Thier K, Pirker C, Höger H, Ambros IM, Ambros PF, Berger W, Bittner RE |
| PLoS genetics. 2011 Apr 14. doi: 10.1371/journal.pgen.1002042. pmc: PMC3077392 |
| PMID: 21533183 |
| Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities. |
| Jantscher F, Pirker C, Mayer CE, Berger W, Sutterluety H |
| Molecular cancer. 2011 Mar 16. pii: 1476-4598-10-28. doi: 10.1186/1476-4598-10-28. pmc: PMC3068985 |
| PMID: 21410931 |
| A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. |
| van Zijl F, Mall S, Machat G, Pirker C, Zeillinger R, Weinhaeusel A, Bilban M, Berger W, Mikulits W |
| Molecular cancer therapeutics. 2011 Mar 1. pii: 1535-7163.MCT-10-0917. doi: 10.1158/1535-7163.MCT-10-0917 |
| PMID: 21364009 |
| Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. |
| Pirker C, Lötsch D, Spiegl-Kreinecker S, Jantscher F, Sutterlüty H, Micksche M, Grusch M, Berger W |
| Experimental dermatology. 2010 Nov 22. doi: 10.1111/j.1600-0625.2010.01182.x |
| PMID: 21087322 |
| EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. |
| Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Jul 7. pii: 1078-0432.CCR-09-0089. doi: 10.1158/1078-0432.CCR-09-0089 |
| PMID: 19584155 |
| Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. |
| Herberger B, Berger W, Puhalla H, Schmid K, Novak S, Brandstetter A, Pirker C, Gruenberger T, Filipits M |
| Molecular cancer therapeutics. 2009 Jun 9. pii: 1535-7163.MCT-09-0003. doi: 10.1158/1535-7163.MCT-09-0003 |
| PMID: 19509244 |
| Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. |
| Vogl UM, Berger W, Micksche M, Pirker C, Lamm W, Pichelmeyer O, Zielinski CC, Schmidinger M |
| Cancer letters. 2009 Jan 25. pii: S0304-3835(08)00945-2. doi: 10.1016/j.canlet.2008.12.013 |
| PMID: 19171421 |
| Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). |
| Heffeter P, Jakupec MA, Körner W, Chiba P, Pirker C, Dornetshuber R, Elbling L, Sutterlüty H, Micksche M, Keppler BK, Berger W |
| Biochemical pharmacology. 2007 Mar 12. pii: S0006-2952(07)00146-3. doi: 10.1016/j.bcp.2007.03.002. pmc: PMC3371634. mid: UKMS48675 |
| PMID: 17445775 |
| Malignant predominantly minigemistocytic glioma in two infants: a distinctive glioma variant? |
| Haberler C, Slavc I, Czech T, Prayer D, Pirker C, Budka H, Hainfellner JA |
| Neuropathology and applied neurobiology. 2007 Mar 15. pii: NAN823. doi: 10.1111/j.1365-2990.2006.00823.x |
| PMID: 17359358 |
| Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. |
| Brachner A, Sasgary S, Pirker C, Rodgarkia C, Mikula M, Mikulits W, Bergmeister H, Setinek U, Wieser M, Chin SF, Caldas C, Micksche M, Cerni C, Berger W |
| Cancer research. 2006 Apr 4. pii: 66/7/3584. doi: 10.1158/0008-5472.CAN-05-2839 |
| PMID: 16585183 |
| The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. |
| Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M, Sutterlüty H, Berger W |
| Journal of cell science. 2006 Jan 17. pii: jcs.02773. doi: 10.1242/jcs.02773 |
| PMID: 16418217 |
| Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. |
| Okamoto I, Pirker C, Bilban M, Berger W, Losert D, Marosi C, Haas OA, Wolff K, Pehamberger H |
| Neoplasia (New York, N.Y.). 2005 Jun 21. pmc: PMC1501156 |
| PMID: 15967107 |
| 227 Einträge | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 › » |
Seite 1 / 12
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
